ReviewNature reviews. Urology2015
Switching and withdrawing hormonal agents for castration-resistant prostate cancer.
Review in Nature reviews. Urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 75 citations in OpenAlex.
- Androgen Receptor T878A and L702H Alterations Define Subsets of Prostate Cancer Patients with Distinct Outcomes to Androgen Receptor Pathway Inhibitors.International journal of molecular sciences · 2026Article
- Evolving Treatments and Resistance Mechanisms in Prostate Cancer Therapeutics.ACS pharmacology & translational science · 2026Review
- Deciphering Complexity: The Molecular Landscape of Castration-Resistant Prostate Cancer.Surgical pathology clinics · 2025Review
- Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications.Cancers · 2024Review
- Article
- International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.Pharmacological reviews · 2023Review
- A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high-risk prostate cancer.IJU case reports · 2023Article
- Macrophages and bone metastasis.The Journal of experimental medicine · 2023Article
- Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Cell Line Characteristics Predict Subsequent Resistance to Androgen Receptor-Targeted Agents (ARTA) in Preclinical Models of Prostate Cancer.Frontiers in oncology · 2022Article
- Clinical implications of genomic alterations in metastatic prostate cancer.Prostate cancer and prostatic diseases · 2021Review
- Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor.International journal of molecular sciences · 2021Article
- Article
- Identification of favorable subgroups for alternative anti-androgen therapy in castration-resistant prostate cancer.Molecular and clinical oncology · 2019Article
- Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer.Oncogene · 2019Article
- Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.International journal of cancer · 2018Article
- Abiraterone acetate withdrawal syndrome: Speculations on the underlying mechanisms.Oncology letters · 2018Article
- Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.Journal of the National Cancer Institute · 2017Article
- Clinical relevance of androgen receptor alterations in prostate cancer.Endocrine connections · 2017Review
- STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
The antiandrogen withdrawal syndrome (AAWS) is characterized by tumour regression and a decline in serum PSA on discontinuation of antiandrogen therapy in patients with prostate cancer. This phenomenon has been best described with the withdrawal of the nonsteroidal antiandrogens, bicalutamide and flutamide, but has also been reported with a wide range of hormonal agents. Mutations that occur in advanced prostate cancer and induce partial activation of the androgen receptor (AR) by hormonal agents have been suggested as the main causal mechanism of the AAWS. Corticosteroids, used singly or in conjunction with abiraterone, docetaxel and cabazitaxel might also be associated with the AAWS. The discovery of the Phe876Leu mutation in the AR, which is activated by enzalutamide, raises the possibility of withdrawal responses to novel hormonal agents. This Review focusses on the molecular mechanisms responsible for withdrawal responses, the role of AR mutations in the development of treatment resistance, and the evidence for the sequential use of antiandrogens in prostate cancer therapy. The implications of AR mutations for the development of novel drugs that target the AR are discussed, as are the challenges associated with redefining the utility of older treatments in the current therapeutic landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.